Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.46 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.46 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.46 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.39 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.39 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL159722 | 1.00 | TAAR1 (0.46) | TAAR1HTR2CHTR2AHTR2BNPSR1 | |
| Malonic Acid SCHEMBL160930 | 0.88 | TAAR1 (0.47) | TAAR1HTR2CHTR2AHTR2BNPSR1 | |
| Succinic Acid SCHEMBL161276 | 0.88 | TAAR1 (0.47) | TAAR1HTR2CHTR2AHTR2BNPSR1 | |
| Glycolic Acid SCHEMBL162065 | 0.88 | TAAR1 (0.47) | TAAR1HTR2CHTR2AHTR2BNPSR1 | |
| SCHEMBL163850 | 0.87 | HTR2C (0.57) | TAAR1HTR2CHTR2AHTR2BPRCP | |
| SCHEMBL162669 | 0.87 | HTR2C (0.57) | TAAR1HTR2CHTR2AHTR2BPRCP | |
| Bromide SCHEMBL161200 | 0.86 | HTR2C (0.56) | TAAR1HTR2CHTR2AHTR2BPRCP | |
| Iodide SCHEMBL162026 | 0.86 | HTR2C (0.56) | TAAR1HTR2CHTR2AHTR2BPRCP | |
| Adipic Acid SCHEMBL161399 | 0.86 | HTR2C (0.48) | TAAR1HTR2CHTR2AHTR2BNPSR1 | |
| Adipic Acid SCHEMBL174687 | 0.86 | HTR2C (0.48) | TAAR1HTR2CHTR2AHTR2BNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012030953-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |